Tissue Repair Receives second US patent for Glucoprime
- Tissue Repair (TRP) receives a second US patent for its topical skin treatment active ingredient, Glucoprime
- Glucoprime is an active pharmaceutical ingredient (API) used to treat skin conditions like burns, pressure ulcers and post-procedure wounds whether it be surgical or cosmetic
- This latest patent grants TissueRepair with exclusive rights to use Glucoprime as a topical application to treat a large number of skin conditions
- It follows TRP’s first patent approval in April 2022 which granted the company exclusive rights to the method of manufacturing
- TRP shares are up 6.45 per cent to close at 33 cents